Loading…
Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
89pct
45d open
vs 5,086 other S bills in the 116th — cohort avg 30d
Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 This bill makes significant changes to the regulation by the Food and Drug Administration (FDA) of nonprescription (i.e., over-the-counter or OTC) drugs. The bill establishes a new approval process for OTC medications. Specifically, it creates an FDA administrative order process for the evaluation of OTC products, replacing the present notice and comment rulemaking approach. Under the new process, the FDA may issue an administrative order determining that a specific OTC drug, class of drugs, or combination is generally regarded as safe and effective and not subject to the new drug application process. The FDA may also use the administrative order process to (1) determine that a drug, class of drugs, or combination poses an imminent hazard to the public health; or (2) require labeling changes to mitigate a significant or unreasonable risk of a serious adverse event associated with use of the drug. The bill provides for market exclusivity under certain circumstances. For drugs determined to be generally regarded as safe and effective pursuant to an administrative order requested by a sponsor (rather than initiated by the FDA), the requestor is granted 18 months of market exclusivity. This market exclusivity applies to an OTC drug with a new active ingredient or if the requestor conducted new human studies to get approval. The bill allows a sponsor of a nonprescription sunscreen active ingredient or a combination of such ingredients that was subject to a proposed sunscreen order to transition to the administrative order process. Market exclusivity provisions also apply to new sunscreen active ingredients. The FDA must establish a user fee program for OTC drugs.
Yes
91
No
2
Present
0
Not Voting
7
Party Breakdown
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (18)
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Received in the House.
Message on Senate action sent to the House.
Passed Senate without amendment by Yea-Nay Vote. 91 - 2. Record Vote Number: 389. (consideration: CR S6921-6930; text: CR S6921-6930)
SenatePassed/agreed to in Senate: Passed Senate without amendment by Yea-Nay Vote. 91 - 2. Record Vote Number: 389.(consideration: CR S6921-6930; text: CR S6921-6930)
SenatePlaced on Senate Legislative Calendar under General Orders. Calendar No. 290.
Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander without amendment. Without written report.
Committee on Health, Education, Labor, and Pensions. Ordered to be reported without amendment favorably.
Bills with similar content found using semantic analysis.
Sources: Congress.gov · House Clerk roll-call votes
| #389 | senate | On Passage of the Bill | Bill Passed (91-2) | December 10, 2019 |
2020 · fourth_quarter · Budget/Appropriations
Issues related to implementation of FY 2020 Energy and Water Appropriations bills (H.R. 2470/S. 2740). Issues related to COVID-19 Relief funding. Issues related to program funding, grants, in FY 21, Energy and Water, Interior and Related Agencies, Defense, Homeland Security Appropriation bills (P.L. 116-260).
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Oceanic & Atmospheric Administration (NOAA), SENATE, U.S. Coast Guard (USCG), U.S. Fish & Wildlife Service (USFWS)
2020 · fourth_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions - Issues related to social determinants of health - H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions - H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions. - H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions - S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions - S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions - S.3780, "HOME Act", regarding all provisions - S.3781, "PART Act", regarding all provisions - Issues related to diversity in clinical trials - Issues related to 340B - S.4613, The Contact Lens Rule Modernization Act, regarding all provisions - H.R.3107, "Improving Seniors Timely Access to Care Act of 2019, regarding all provisions - Executive Order 13948: Lowering Drug Prices by Putting America First - Executive Order 13939: Lowering Prices for Patients by Eliminating Kickbacks to Middlemen - Executive Order 13938: Increasing Drug Importation To Lower Prices for American Patients - Executive Order 13937: Access to Affordable Life-Saving Medications -H.R.133 - Consolidated Appropriations Act, 2021, including legislation regarding average sales price (ASP) reporting requirements for certain hyaluronic acid (HA) products that are classified as devices, but reimbursed as drugs under Medicare Part B
2020 · fourth_quarter · Manufacturing
H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 -- To reauthorize certain programs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to public health security and all-hazards preparedness and response, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes. H.R.648 - Consolidated Appropriations Act, 2019 -- Making appropriations for the fiscal year ending September 30, 2019, and for other purposes. Includes language authorizing the collection of Monograph Reform user fees. H.J.Res.28 - Further Additional Continuing Appropriations Act, 2019 - This joint resolution provides continuing FY2019 appropriations to several federal agencies through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. H.J.Res.31 - Consolidated Appropriations Act, 2019 -- This joint resolution provides continuing FY2019 appropriations for the Department of Homeland Security (DHS) through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. It is known as a continuing resolution (CR) and ends the partial DHS shutdown that began on December 22, 2018, because the existing CR expired and the FY2019 DHS appropriations bill has not been enacted. H.R.268 - Supplemental Appropriations Act, 2019 -- This bill provides $12.1 billion in FY2019 supplemental appropriations to several federal departments and agencies for expenses related to the consequences of recent wildfires, hurricanes, volcanos, earthquakes, typhoons, and other natural disasters. S.726 - Personal Care Products Safety Act -- To amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. Cosmetic Safety Enhancement Act of 2019 (Pallone/Shimkus discussion draft) -- To amend the Federal Food, Drug, and Cosmetic Act to improve cosmetic safety, and for other purposes H.R.3443 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 S.1895 - Lower Health Care Costs Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.4296 - Safe Cosmetics and Personal Care Products Act of 2019 Udall/Lowenthal consumer products plastics outline, proposal to address consumer plastics issues. No bill number. H.R.2296/S.1391 - More Efficient Tools to Realize Information for Consumers Act S.2740 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5279 - Cosmetic Safety Enhancement Act of 2019 21st Century Cures Act 2.0 (No bill number) H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R.748 - CARES Act Critical infrastructure and supply chain HR 8837 -- Continuing Appropriations Act, 2021 and Other Extensions Act H.R.133 - Consolidated Appropriations Act, 2021
2020 · third_quarter · Budget/Appropriations
Issues related to implementation of FY 2020 Energy and Water Appropriations bills (H.R. 2470/S. 2740). Issues related to COVID-19 Relief funding. Issues related to program funding, grants, in FY 21, Energy and Water, Interior and Related Agencies, Defense, Homeland Security Appropriation bills.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Oceanic & Atmospheric Administration (NOAA), SENATE, U.S. Coast Guard (USCG), U.S. Fish & Wildlife Service (USFWS)
2020 · third_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions - Issues related to social determinants of health - H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions - H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions. - H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions - S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions - S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions - S.3780, "HOME Act", regarding all provisions - S.3781, "PART Act", regarding all provisions - Issues related to diversity in clinical trials - Issues related to 340B - S.4613, The Contact Lens Rule Modernization Act, regarding all provisions - H.R.3107, "Improving Seniors Timely Access to Care Act of 2019, regarding all provisions - Executive Order 13948: Lowering Drug Prices by Putting America First - Executive Order 13939: Lowering Prices for Patients by Eliminating Kickbacks to Middlemen - Executive Order 13938: Increasing Drug Importation To Lower Prices for American Patients - Executive Order 13937: Access to Affordable Life-Saving Medications
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
| Senate |
| Referred to |
| October 30, 2019 |
| October 30, 2019 |
| Democratic |
| WA |
| Robert P. Casey, Jr. | Democratic | PA |
| HR 19 |
116th |
| Related bill |
Client expense: $1,450,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Client expense: $146,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.
Client expense: $860,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2020 · third_quarter · Manufacturing
H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 -- To reauthorize certain programs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to public health security and all-hazards preparedness and response, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes. H.R.648 - Consolidated Appropriations Act, 2019 -- Making appropriations for the fiscal year ending September 30, 2019, and for other purposes. Includes language authorizing the collection of Monograph Reform user fees. H.J.Res.28 - Further Additional Continuing Appropriations Act, 2019 - This joint resolution provides continuing FY2019 appropriations to several federal agencies through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. H.J.Res.31 - Consolidated Appropriations Act, 2019 -- This joint resolution provides continuing FY2019 appropriations for the Department of Homeland Security (DHS) through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. It is known as a continuing resolution (CR) and ends the partial DHS shutdown that began on December 22, 2018, because the existing CR expired and the FY2019 DHS appropriations bill has not been enacted. H.R.268 - Supplemental Appropriations Act, 2019 -- This bill provides $12.1 billion in FY2019 supplemental appropriations to several federal departments and agencies for expenses related to the consequences of recent wildfires, hurricanes, volcanos, earthquakes, typhoons, and other natural disasters. S.726 - Personal Care Products Safety Act -- To amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. Cosmetic Safety Enhancement Act of 2019 (Pallone/Shimkus discussion draft) -- To amend the Federal Food, Drug, and Cosmetic Act to improve cosmetic safety, and for other purposes H.R.3443 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 S.1895 - Lower Health Care Costs Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.4296 - Safe Cosmetics and Personal Care Products Act of 2019 Udall/Lowenthal consumer products plastics outline, proposal to address consumer plastics issues. No bill number. H.R.2296/S.1391 - More Efficient Tools to Realize Information for Consumers Act S.2740 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5279 - Cosmetic Safety Enhancement Act of 2019 21st Century Cures Act 2.0 (No bill number) H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R.748 - CARES Act Critical infrastructure and supply chain HR 8837 -- Continuing Appropriations Act, 2021 and Other Extensions Act
Client expense: $140,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.
2020 · first_quarter · Medical/Disease Research/Clinical Labs
Over the counter drug approval process for sunscreen ingredients; Implementation of Public Law 113-195, the Sunscreen Innovation Act; House and Senate FY 2021 Ag-FDA Appropriations bills and reports; Sunscreen use in schools; Sunscreen provisions in H.R. 3443 and S.2740, Over-the-Counter Monograph Safety, Innovation and Reform Act of 2019; Issues related to state bans on sunscreen ingredients; Issues related to sunscreen use and coral reefs.
Client expense: Not reported · Firm income: $60,000
Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Oceanic & Atmospheric Administration (NOAA), SENATE
2020 · second_quarter · Pharmacy
General issues related to over the counter pharmaceuticals and pharmaceutical supply chain. H.R. 3443/S.2740, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Health Issues
Issues related to the over the counter drug monograph process including H. R. 3443/S.2740, the Over-the-counter Monograph Safety, Innovation, and Reform Act of 2019. Issues related to sunscreen. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act. H.R. 5279, Cosmetic Safety Enhancement Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Budget/Appropriations
Issues related to implementation of FY 2020 Energy and Water Appropriations bills (H.R. 2470/S. 2740). Issues related to COVID-19 Relief funding. Issues related to program funding, grants, in FY 21, Energy and Water, Interior and Related Agencies, Defense, Homeland Security Appropriation bills.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Oceanic & Atmospheric Administration (NOAA), SENATE, U.S. Coast Guard (USCG), U.S. Fish & Wildlife Service (USFWS)
2020 · second_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions - Issues related to social determinants of health - H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions - H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions. - H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions - S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions - S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions - S.3780, "HOME Act", regarding all provisions - S.3781, "PART Act", regarding all provisions - Issues related to diversity in clinical trials
Client expense: $1,760,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2020 · second_quarter · Health Issues
S. 726 Personal Care Products Safety Act H.R. 748 The CARES Act; S. 2740 Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 Policies that impact the cleaning products industry due to the impacts of COVID 19 Legislation associated with ingredient disclosure. H.R. 6379, the Take Responsibility for Workers and Families Act The Disaster and Emergency Pricing Abuse Prevention Act The Ending Price-Gouging During Emergencies Act Issues associated with OTC monograph reform
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Consumer Issues/Safety/Products
H.R. 1816, Children's Product Warning Label Act of 2019; H.R. 5279, Cosmetic Safety Enhancement Act; H.R. 5141/S. 2886, Humane Cosmetics Act - Issues related to regulation of cosmetic animal testing; S. 2740, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019; H.R. 6058, Stopping Harmful Offers on Platforms by Screening Against Fakes in E-commerce (SHOP SAFE) Act of 2020; S. 3431, Integrity, Notification, and Fairness in Online Retail Marketplaces for Consumers Act; S. ___, Hand Sanitizer Guidance Extension Act of 2020; Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry; House Agriculture Appropriations FY2021 - alternatives to animal testing, Cannabidiol enforcement of cannabis derived products, chemicals in cosmetics and sunscreens
Client expense: $450,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)
2020 · second_quarter · Manufacturing
H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 -- To reauthorize certain programs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to public health security and all-hazards preparedness and response, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes. H.R.648 - Consolidated Appropriations Act, 2019 -- Making appropriations for the fiscal year ending September 30, 2019, and for other purposes. Includes language authorizing the collection of Monograph Reform user fees. H.J.Res.28 - Further Additional Continuing Appropriations Act, 2019 - This joint resolution provides continuing FY2019 appropriations to several federal agencies through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. H.J.Res.31 - Consolidated Appropriations Act, 2019 -- This joint resolution provides continuing FY2019 appropriations for the Department of Homeland Security (DHS) through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. It is known as a continuing resolution (CR) and ends the partial DHS shutdown that began on December 22, 2018, because the existing CR expired and the FY2019 DHS appropriations bill has not been enacted. H.R.268 - Supplemental Appropriations Act, 2019 -- This bill provides $12.1 billion in FY2019 supplemental appropriations to several federal departments and agencies for expenses related to the consequences of recent wildfires, hurricanes, volcanos, earthquakes, typhoons, and other natural disasters. S.726 - Personal Care Products Safety Act -- To amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. Cosmetic Safety Enhancement Act of 2019 (Pallone/Shimkus discussion draft) -- To amend the Federal Food, Drug, and Cosmetic Act to improve cosmetic safety, and for other purposes H.R.3443 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 S.1895 - Lower Health Care Costs Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.4296 - Safe Cosmetics and Personal Care Products Act of 2019 Udall/Lowenthal consumer products plastics outline, proposal to address consumer plastics issues. No bill number. H.R.2296/S.1391 - More Efficient Tools to Realize Information for Consumers Act S.2740 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5279 - Cosmetic Safety Enhancement Act of 2019 21st Century Cures Act 2.0 (No bill number) H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R.748 - CARES Act Critical infrastructure and supply chain
Client expense: $128,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.
2020 · second_quarter · Health Issues
FY 2021 appropriations for the US Food and Drug Administration; The Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 (S. 2740), which was included in Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medical/Disease Research/Clinical Labs
Over the counter drug approval process for sunscreen ingredients; Implementation of Public Law 113-195, the Sunscreen Innovation Act; House and Senate FY 2021 Ag-FDA Appropriations bills and reports; Sunscreen use in schools; Sunscreen provisions in H.R. 3443 and S.2740, Over-the-Counter Monograph Safety, Innovation and Reform Act of 2019; Issues related to state bans on sunscreen ingredients; Issues related to sunscreen use and coral reefs.
Client expense: Not reported · Firm income: $50,000
Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Oceanic & Atmospheric Administration (NOAA), SENATE
2020 · first_quarter · Health Issues
general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform in CARES Act; issues related to HSA/FSA in CARES Act; issues related to Vaccine provisions in CARES Act; issues related to prescription to over-the-counter switch; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; issues related to Coronavirus COVID-19; issues related to Copay Accumulators; issues related to RSV access; issues related to HR.3433- Over the counter Monograph Safety, Innovation and Reform Act 2019; issues related to S.2158- Newborn Screening Saves Lives; and issues related to CMMI- Insulin Demo.
Client expense: $1,750,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Pharmacy
S.2740 OTC Monograph
Client expense: Not reported · Firm income: $50,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)
2020 · first_quarter · Budget/Appropriations
Issues related to implementation of FY 2020 Energy and Water Appropriations bills (H.R. 2470/S. 2740). Issues related to COVID-19 Relief funding.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Oceanic & Atmospheric Administration (NOAA), SENATE, U.S. Coast Guard (USCG), U.S. Fish & Wildlife Service (USFWS)
2020 · first_quarter · Health Issues
Issues regarding access to dental services. Monitored H.R. 1835, Consensual Donation and Research Integrity Act of 2019. S. 1895, Lower Health Care Costs Act of 2019, H.R. 2328, Reauthorizing and Extending Americas Community Health Act and issues regarding surprise billing and exempt benefits. H.R. 3630, No Surprises Act. S.2740 / H.R.3443, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019. Coronavirus Aid, Relief and Economic Security "CARES Act," P.L. 116-136, as it relates to over-the-counter monograph safety and surprise billing. Monitored issues related to Indian Health Services. H.R.1379, the Ensuring Lasting Smiles Act. Monitored issues related to H.R. 5800, Ban Surprise Billing Act. Monitored issues related to H.R. 2339, the Reversing the Youth Tobacco Epidemic Act of 2019. Monitored issues related to Section 1557 of the Patient Protection and Affordable Care Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Treasury, Dept of
2020 · first_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions
Client expense: $1,480,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2020 · first_quarter · Manufacturing
H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 -- To reauthorize certain programs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to public health security and all-hazards preparedness and response, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes. H.R.648 - Consolidated Appropriations Act, 2019 -- Making appropriations for the fiscal year ending September 30, 2019, and for other purposes. Includes language authorizing the collection of Monograph Reform user fees. H.J.Res.28 - Further Additional Continuing Appropriations Act, 2019 - This joint resolution provides continuing FY2019 appropriations to several federal agencies through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. H.J.Res.31 - Consolidated Appropriations Act, 2019 -- This joint resolution provides continuing FY2019 appropriations for the Department of Homeland Security (DHS) through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. It is known as a continuing resolution (CR) and ends the partial DHS shutdown that began on December 22, 2018, because the existing CR expired and the FY2019 DHS appropriations bill has not been enacted. H.R.268 - Supplemental Appropriations Act, 2019 -- This bill provides $12.1 billion in FY2019 supplemental appropriations to several federal departments and agencies for expenses related to the consequences of recent wildfires, hurricanes, volcanos, earthquakes, typhoons, and other natural disasters. S.726 - Personal Care Products Safety Act -- To amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. Cosmetic Safety Enhancement Act of 2019 (Pallone/Shimkus discussion draft) -- To amend the Federal Food, Drug, and Cosmetic Act to improve cosmetic safety, and for other purposes H.R.3443 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 S.1895 - Lower Health Care Costs Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.4296 - Safe Cosmetics and Personal Care Products Act of 2019 Udall/Lowenthal consumer products plastics outline, proposal to address consumer plastics issues. No bill number. H.R.2296/S.1391 - More Efficient Tools to Realize Information for Consumers Act S.2740 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5279 - Cosmetic Safety Enhancement Act of 2019 21st Century Cures Act 2.0 (No bill number) H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R.748 - CARES Act Critical infrastructure and supply chain
Client expense: $165,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of
2020 · first_quarter · Health Issues
Cosmetic safety reform S. 726 Personal Care Products Safety Act H.R. 748 The CARES Act; S. 2740 Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 Policies that impact the cleaning products industry due to the impacts of COVID 19 Legislation associated with ingredient disclosure. H.R. 6379, the Take Responsibility for Workers and Families Act The Disaster and Emergency Pricing Abuse Prevention Act The Ending Price-Gouging During Emergencies Act Issues associated with OTC monograph reform
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
Issues related to cosmetic safety reform, OTC monograph reform, and ingredient disclosure. Policies that impact the cleaning products industry due to COVID-19 and efforts to provide support with effective hand hygiene products and services. S.726, Personal Care Products Safety Act. S.2740, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019. H.R.6379, Take Responsibility for Workers and Families Act. The Disaster and Emergency Pricing Abuse Prevention Act. The Ending Price-Gouging During Emergencies Act. H.R.748, CARES Act (P.L.116-136).
Client expense: $270,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2020 · first_quarter · Health Issues
Issues related to the over the counter drug monograph process including H. R. 3443/S.2740, the Over-the-counter Monograph Safety, Innovation, and Reform Act of 2019. Issues related to sunscreen. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Pharmacy
General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process including H. R. 3443/S2740, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Consumer Issues/Safety/Products
H.R. 1816, Children's Product Warning Label Act of 2019; H.R. 5017, Natural Cosmetics Act; H.R. 5279, Cosmetic Safety Enhancement Act; H.R. 4296, Safe Cosmetics and Personal Care Products Act of 2019; H.R. 5141/S. 2886, Humane Cosmetics Act - Issues related to regulation of cosmetic animal testing; S. 2740, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019; H.R. 6058, Stopping Harmful Offers on Platforms by Screening Against Fakes in E-commerce (SHOP SAFE) Act of 2020; Issues related to the ingredients in hand sanitizer and the availability of hand sanitizer; Issues related to the classification of personal care/hygiene manufacturers as essential places of business
Client expense: $500,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)
2020 · first_quarter · Health Issues
Discussions pertaining to the cost of dental care in America HR 3 Lower Drug Costs Now Act of 2019 - discussions pertaining to proposals for expansion of Medicare benefits Monitored HR 1393 Medicare Dental, Vision, and Hearing Benefit Act of 2019 Monitored issues related to the pricing and prescribing of pharmaceutical drugs and the impact on dental providers Monitored HR 2951 Medicare Dental Benefit Act of 2019 Monitored S 22 Medicare Dental Benefit Act of 2019 Monitored HR 3502 Protecting People From Surprise Medical Bills Act Monitored S 1895 Lower Health Care Costs Act Monitored S 2740 Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
FY 2021 appropriations for the US Food and Drug Administration; The Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 (S. 2740), which was included in Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Budget/Appropriations
H.R.2968 / S.2474, Department of Defense Appropriations Act, 2020, Titles III and IV, all provisions relating to High Performance Computing and Advanced Technology. H.R.2960 / S.2740, Energy and Water Development and Related Agencies Appropriations Act, 2020, Title III, all provisions relating to Advanced Simulation and Computing; Title III, all provisions relating to Advanced Scientific Computing Research. H.R.3055 / S.2584, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2020, Title III, all previsions relating to NOAA supercomputing.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Budget/Appropriations
H.R. 3055/S. 2584 Commerce, Justice, Science and Related Agencies Appropriations Act, 2020, Title I, all provisions relating to production weather, oceanic and atmospheric research, system acquisition, and research supercomputing (on behalf of Cray); weather data (on behalf of PlanetIQ), and unmanned surface vehicles (on behalf of Saildrone); and Title III, all provisions relating to production weather, oceanic and atmospheric research, system acquisition, and research supercomputing (on behalf of Cray). H.R. 2968 /S. 2474, Department of Defense Appropriations Act, 2020, Title III, all provisions relating to Navy shipbuilding (on behalf of Austal USA), unmanned aerial vehicles (on behalf of General Atomics Aeronautical Systems Inc), high performance computing (on behalf of Cray and Hewlett-Packard Enterprise), edge computing (on behalf of Hewlett-Packard Enterprise), tactical radios (on behalf of Thales USA), and surveying equipment or systems (on behalf of Trimble); Title IV, all provisions relating to assured access to space (on behalf of Arianespace), ship development (on behalf of Austal USA), biomedical technology (on behalf of Battelle Memorial Institute), high performance computing (on behalf of Cray and Hewlett Packard Enterprise), edge computing (on behalf of Hewlett-Packard Enterprise), advanced power electronics (on behalf of Cree), tactical and intelligence data analysis (on behalf of Esri), unmanned aerial vehicles (on behalf of General Atomics Aeronautical Systems Inc), unexplained physiological episode research and human performance in extreme environments (on behalf of the Florida Institute for Human Machine Cognition), weather data (on behalf of PlanetiQ), aerospace sensors and technology transition (on behalf of Wright State Research Institute), major test and evaluation investment (on behalf of SRI International); and title VI, all provisions relating to blood products (on behalf of Cerus). H.R. 2960 /S. 2740 Energy and Water Development Act, 2020, Title III, all provisions relating to advanced scientific computing research and advanced simulation and computing (on behalf of Cray and Hewlett-Packard Enterprise), and advanced robotics (on behalf of Florida Institute for Human Machine Cognition). H.R. 3052/S. 2580, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2020, Title I, all provisions relating to U.S. Geological Surveys maps (on behalf of Esri) and U.S. Park Service procurement of surveying equipment or systems (on behalf of Trimble). H.R. 3931/S. 2582, Department of Homeland Security Appropriations Act, 2020, Title II, all provisions relating to enterprise information geospatial services (on behalf of ESRI). H.R. 2740/S. ____Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2020, Title II, all provisions relating to blood products (on behalf of Cerus). H.S. 3163 /S. 2520 Department of Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act, 2020, Title I, all provisions relating to use of geospatial technologies (on behalf of Esri) and funding for infrastructure (on behalf of Trimble).
Client expense: Not reported · Firm income: Not reported
2019 · fourth_quarter · Health Issues
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to prescription to over-the-counter switch; issues related to compulsory licensing; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; and issues related to H.R. 19 "Lower Costs, More Cures Act of 2019" .
Client expense: $783,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Health Issues
H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release (FAIR) of Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1922: Restoring Access to Medication Act of 2019 - Provisions related to prescription drug access H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: Drug Price Transparency for Medicare Patients Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 3415: Real-Time Beneficiary Drug Cost Bill - Provisions related to drug pricing transparency H.R. 3947: Competition Prescription Act of 2019 - Provisions related to prescription drug pricing, patents, and other provisions H.R. 4106: Responsibility in Drug Advertising Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 4158: CURE High Drug Prices Act - Provisions related to prescription drug pricing and transparency H.R. 4244: MAGIC Act - Provisions related to FDA approval pathways H.R. 4439: Creating Hope Reauthorization Act - Provisions related to rare disease priority review vouchers H.R. 4538: Closing Loopholes for Orphan Drugs Act - Provisions related to 340B prescription drug exclusions H.R. 4633: Investing in Safety and Innovation Act of 2019 - Provisions related to FDA programs reauthorization H.R. 4640: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 - Provisions related to prescription drug pricing and negotiation H.R. 4667: Biomedical Innovation Expansion Act of 2019 - Provisions related to NIH programs reauthorization H.R. 4710: Pharmaceutical Independence Long-Term Readiness Reform Act - Provisions related to the supply chain H.R. 4711: No Tax Breaks for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising H.R. 4812: Ensuring Compliance Against Drug Diversion Act of 2019 - Provisions related to registrations under the Controlled Substances Act H.R. 4866: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019 - Provisions related to designation of universities as centers of excellence supporting manufacturing H.R. 4963: Stop the Importation and Manufacturing of Synthetic Analogues Act of 2019 - Provisions related to synthetic analogues H.R. 5031: Medical Innovation Act of 2019 - Provisions related to prescription drug manufacturer taxation and supplemental fees H.R. 5198: Patients' Right to Know Their Medication Act of 2019 - Provisions related to prescription drug labeling H.R. 5239: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency H.R. 5304: PBM Transparency in Prescription Drug Costs Act - Provisions related to prescription drug pricing transparency H.R. 5381: International Pharmaceutical Transparency Act of 2019 - Provisions related to prescription drug labeling H.R. 5442: To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require pharmacies to disclose any differential between the cost of a prescription drug based on whether certain individuals use prescription drug coverage to acquire such drug, and for other purposes. - Provisions related to prescription drug pricing and transparency H.R. 5497: Conditional Approval Act - Provisions related to approval pathway S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 658: Accelerated Drug Approval for Prescription Therapies Act - Provisions related to FDA drug approvals S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1250: American Cures Act - Provisions related to pharmaceutical research and development S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 2004: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug pricing S. 2161: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity S. 2723: Mitigating Emergency Drug Shortages Act - Provisions related to prescription drug pricing transparency and other provisions S. 2897: Patient-Centered Outcomes Research Institute Reauthorization Act - Provisions related to PCORI reauthorization Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues PDUFA implementation policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Drug compounding policy issues including federal oversight of compounded drugs Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49) Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45) Monograph Reform, HSA/FSAs S 2740 - Over-the-Counter Monograph Safety S1872/HR5076, Protecting Seniors Through Immunization Act S1654/HR1973, Vaccine Access Improvement Act
Client expense: $700,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
2019 · fourth_quarter · Health Issues
Legislative outreach and monitoring related to healthcare issues. S. 2740, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019.
Client expense: Not reported · Firm income: Not reported
Government targets: SENATE
2019 · fourth_quarter · Budget/Appropriations
H.R.2968 / S.2474, Department of Defense Appropriations Act, 2020, Titles III and IV, all provisions relating to High Performance Computing and Advanced Technology. H.R.2960 / S.2740, Energy and Water Development and Related Agencies Appropriations Act, 2020, Title III, all provisions relating to Advanced Simulation and Computing; Title III, all provisions relating to Advanced Scientific Computing Research. H.R.3055 / S.2584, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2020, Title III, all previsions relating to NOAA supercomputing.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Budget/Appropriations
Issues related to FY 2020 Energy and Water Appropriations bills (H.R. 2470/S. 2740).
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Oceanic & Atmospheric Administration (NOAA), SENATE, U.S. Coast Guard (USCG), U.S. Fish & Wildlife Service (USFWS)
2019 · fourth_quarter · Pharmacy
S. 61, Safe and Affordable Drugs from Canada Act (Grassley) - drug importation S. 64, Preserve Access to Affordable Generics and Biosimilars Act (Grassley-Klobuchar) - prohibiting pay-for-delay settlements S. 73, End Taxpayer Subsidies for Drug Ads Act (Shaheen) - prohibiting tax deduction for DTC advertising expenses S. 102, Prescription Drug Price Relief Act (Sanders) - reforms linked to international pricing S. 340, CREATES Act (Leahy) - removing barriers to generic drugs S. 344, Hatch-Waxman Integrity Act (Tillis) - inter partes review process S. 366, FLAT Prices Act (Durbin) - reforms for drugs with sudden price spikes S. 378, Stop Price Gouging Act (Durbin) - excise tax for drugs that have price spikes S. 440, Preserving Access to Cost-Effective Drugs Act (Cotton) - sovereign immunity and Inter Partes Review process S. 474, SPIKE Act (Wyden) - justification for drug price increases S. 476, Creating Transparency to Have Drug Rebates Unlocked Act (Wyden) - drug price transparency S. 637, CURE High Drug Prices Act (Blumenthal) - remedies for price gouging S. 657, Point of Sale Rebates (Braun) S. 659, Biologic Patent Transparency Act (Collins) - patent disclosure requirements S. 660, Efficiency and Transparency in Petitions Act (Braun) - FDA citizen petition process S. 844, Short on Competition Act (Klobuchar) - remedies for marginally competitive drug markets S. 977, Transparency Drug Pricing Act (Scott) - transparency and drug pricing reforms S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act (Cassidy) - preventing evergreening of patent protections S. 1224, Stop STALLING Act (Klobuchar) - citizen petition process S. 1227, Prescription Pricing for the People Act (Grassley) - FTC report on role of PBMs and allegations of anticompetitive conduct by manufacturers of sole-source drugs S. 1384, Prescription Drug Rebate Reform Act (Romney-Braun) - prescription drug cost sharing S. 1416, Affordable Prescriptions for Patients Act (Cornyn) - product hopping, patent thickets S. 1664, Prescription Drug Price Reporting Act (Scott) - prescription drug price reporting S. 2247, Phair Relief Act of 2019 (Kennedy)-transparency around price concessions for drugs S. 2387, We Protect American Investment in Drugs Act (Van Hollen)-drug pricing S. 2543, Prescription Drug Pricing Reduction Act of 2019 (Grassley)-Drug pricing S. 2740, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 (Isakson) - regulations re nonprescription drugs that are marketed without an approved new drug application S. 3052, United States-Mexico-Canada Agreement Implementation Act (Grassley) - drug pricing S. 3067, Non-Opioids Prevent Addiction In the Nation Act (Capito) - non-opioid treatments S. 3092, Expanding Access to Low-Cost Generics Act of 2019 (Smith) - exclusivity period H.R. 3, Lower Drug Costs Now Act of 2019 (Pallone)-drug pricing H.R. 465, Prescription Drug Price Relief Act (Khanna) - reforms linked to international pricing H.R. 478, Safe and Affordable Drugs from Canada Act (Pingree) - drug importation H.R. 938, BLOCKING Act (Schrader) - changes to 180-day period of market exclusivity for first generic applicant H.R. 965, CREATES Act (Cicilline) - removing barriers to generic drugs H.R. 985, FAST Generics Act (Welch) - removing barriers to generic drugs H.R. 990, Hatch-Waxman Integrity Act (Flores) - inter partes review process H.R. 1093, Stop Price Gouging Act (Pocan) - excise tax for drugs that have price spikes H.R. 1188, FLAT Prices Act (Golden) - reforms for drugs with sudden price spikes H.R. 1344, Competitive DRUGS Act (Doggett) - prohibiting pay-for-delay agreements H.R. 1419, Public Option Deficit Reduction Act (DeFazio) - public option H.R. 1499, Protecting Consumer Access to Generic Drugs Act (Rush) - prohibiting pay-for-delay agreements H.R. 1503, Orange Book Transparency Act (Kelly) - removal of invalidated patents from Orange Book H.R. 1506, FAIR Generics Act (Barragan) - changes to 180-day period of market exclusivity for first generic applicant H.R. 1520, Purple Book Continuity Act (Eshoo) - access to updated information on biologics and biosimilars H.R. 2038, State-Based, Market-Oriented Prescription Drug Negotiations Act (Meadows) - drug price negotiations H.R. 2064, Sunshine for Samples Act (Chu) - reporting requirements on drug samples H.R. 2069, SPIKE Act (Horsford) -justification for drug price increases H.R. 2087, Drug Price Transparency Act (Doggett) - reporting of drug pricing data under Medicare Part B H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (Neal) - transparency in drug pricing H.R. 2115, Public Disclosure of Drug Discounts Act (Spanberger) - disclosure of negotiated Rx discounts H.R. 2279, Safe Step Act (Ruiz) - exceptions process for medication step therapy H.R. 2296, FAIR Drug Pricing Act (Schakowsky) - transparency requirements and justification for high list prices and drug price increases H.R. 2374, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Jeffries) - citizen petition process H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act (Nadler) - prohibiting pay-for-delay agreements H.R. 2376, Prescription Pricing for the People Act (Collins) - FTC study on role of PBMs and competition and transparency in pharmaceutical supply chain H.R. 3379, Price Relief, Innovation, and Competition for Essential Drugs Act (Schakowsky) - exclusivity period for biological products H.R. 3805, Prescription Drug Rebate Reform Act of 2019 (Gallagher)- drug rebates H.R. 3927, PDMPs Help Patients Act of 2019 (McKinley)-integrating SUDs and behavioral health into PDMPs H.R. 3947, Competition Prescription Act of 2019 (Meadows)- drug pricing H.R. 4010, Emergency Access to Insulin Act of 2019 (Craig)- drug pricing H.R. 4106, Responsibility in Drug Advertising Act of 2019 (DeLauro)-transparency in drug pricing H.R. 4244, MAGIC Act (Kelly)-pathways for insulin approval H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (Cicilline)-drug pricing H.R. 4455, BIOSIM Act (Schrader)-access to biosimilars H.R. 4460, Turn the Tide Act (Kuster)-Opioids H.R. 4538, Closing Loopholes for Orphan Drugs Act (Welch)-Access to drugs H.R. 4640, Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 (DeFazio) - direct negotiation H.R. 4712, Fairness in Orphan Drug Exclusivity Act (Dean) - limitations on exclusive approval of orphan drugs H.R. 4810, Opioid Prescription Verification Act of 2019 (David) - dispensing of controlled substances H.R. 4906, Insulin Price Reduction Act (Diana DeGette) - insulin costs H.R. 5304, PBM Transparency in Prescription Drug Costs Act (Schrader) - PBMs H.R. 5364, End Price Gouging for Insulin Act (Beatty) - annual reference price for insulin products H.R. 5430, United States-Mexico-Canada Agreement Implementation Act (Hoyer) - drug pricing H.R. 5442, Lowest Price for Patients Act (Porter) - pharmacies to disclose any differential between the cost of a prescription drug H.R. 5444, Lower Insulin Costs Now Act (Underwood) - lowering insulin costs H.Con.Res. 55, Expressing the sense of Congress on the need to inform American consumers with more balanced purchasing information for prescription drugs through the disclosure of price information in direct-to-consumer (DTC) advertisements. (Burgess)-drug pricing Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Client expense: $2,340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
2019 · fourth_quarter · Consumer Issues/Safety/Products
H.R. 1816, Children's Product Warning Label Act of 2019; H.R. 5017, Natural Cosmetics Act; H.R. 5279, Cosmetic Safety Enhancement Act; H.R. 4296, Safe Cosmetics and Personal Care Products Act of 2019 H.R. 5141/S. 2886, Humane Cosmetics Act - Issues related to regulation of cosmetic animal testing S. 2740/H.R. 3443, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 Combating Counterfeits draft legislation
Client expense: $300,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2019 · fourth_quarter · Health Issues
Discussions pertaining to the cost of dental care in America HR 3 Lower Drug Costs Now Act of 2019 - discussions pertaining to proposals for expansion of Medicare benefits Monitored HR 1393 Medicare Dental, Vision, and Hearing Benefit Act of 2019 Monitored issues related to the pricing and prescribing of pharmaceutical drugs and the impact on dental providers Monitored HR 2951 Medicare Dental Benefit Act of 2019 Monitored S 22 Medicare Dental Benefit Act of 2019 Monitored HR 3502 Protecting People From Surprise Medical Bills Act Monitored S 1895 Lower Health Care Costs Act Monitored S 2740 Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Health Issues
Cosmetic safety reform S. 726 Personal Care Products Safety Act S. 2740 Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Health Issues
Issues regarding access to dental services. Monitored H.R. 1835, Consensual Donation and Research Integrity Act of 2019. S. 1895, Lower Health Care Costs Act of 2019, H.R. 2328, Reauthorizing and Extending Americas Community Health Act and issues regarding surprise billing and exempt benefits. H.R. 3630, No Surprises Act. S.2740, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019. Monitored S. 1541, Tobacco-Free Youth Act regarding increasing the age for purchasing tobacco products.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Health Issues
Cosmetic safety reform; S.726, Personal Care Products Safety Act; S.2740, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019.
Client expense: $260,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2019 · fourth_quarter · Health Issues
Issues related to the over the counter drug monograph process including H. R. 3443/S.2740, the Over-the-counter Monograph Safety, Innovation, and Reform Act of 2019. Issues related to sunscreen. H. R. 1865, the Further Consolidated Appropriations Act of 2020.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Pharmacy
General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process including H. R. 3443/S2740, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019. H. R. 1865, the Further Consolidated Appropriations Act of 2020.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Manufacturing
H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 -- To reauthorize certain programs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to public health security and all-hazards preparedness and response, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes. H.R.648 - Consolidated Appropriations Act, 2019 -- Making appropriations for the fiscal year ending September 30, 2019, and for other purposes. Includes language authorizing the collection of Monograph Reform user fees. H.J.Res.28 - Further Additional Continuing Appropriations Act, 2019 - This joint resolution provides continuing FY2019 appropriations to several federal agencies through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. H.J.Res.31 - Consolidated Appropriations Act, 2019 -- This joint resolution provides continuing FY2019 appropriations for the Department of Homeland Security (DHS) through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. It is known as a continuing resolution (CR) and ends the partial DHS shutdown that began on December 22, 2018, because the existing CR expired and the FY2019 DHS appropriations bill has not been enacted. H.R.268 - Supplemental Appropriations Act, 2019 -- This bill provides $12.1 billion in FY2019 supplemental appropriations to several federal departments and agencies for expenses related to the consequences of recent wildfires, hurricanes, volcanos, earthquakes, typhoons, and other natural disasters. S.726 - Personal Care Products Safety Act -- To amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. Cosmetic Safety Enhancement Act of 2019 (Pallone/Shimkus discussion draft) -- To amend the Federal Food, Drug, and Cosmetic Act to improve cosmetic safety, and for other purposes H.R.3443 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 S.1895 - Lower Health Care Costs Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.4296 - Safe Cosmetics and Personal Care Products Act of 2019 Udall/Lowenthal consumer products plastics outline, proposal to address consumer plastics issues. No bill number. H.R.2296/S.1391 - More Efficient Tools to Realize Information for Consumers Act S.2740 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5279 - Cosmetic Safety Enhancement Act of 2019 21st Century Cures Act 2.0 (No bill number) H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019
Client expense: $177,500 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2019 · fourth_quarter · Medical/Disease Research/Clinical Labs
Over the counter drug approval process for sunscreen ingredients; Implementation of Public Law 113-195, the Sunscreen Innovation Act; House and Senate FY 2020 Ag-FDA Appropriations bills and reports (H.R. 3164 & S.2522); Sunscreen use in schools; Sunscreen provisions in H.R. 3443 and S.2740, Over-the-Counter Monograph Safety, Innovation and Reform Act of 2019; Issues related to state bans on sunscreen ingredients.
Client expense: Not reported · Firm income: $70,000
Government targets: Centers For Disease Control & Prevention (CDC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · third_quarter · Budget/Appropriations
H.R. 3055/S. 2584 Commerce, Justice, Science and Related Agencies Appropriations Act, 2020, Title I, all provisions relating to production weather, oceanic and atmospheric research, system acquisition, and research supercomputing (on behalf of Cray); weather data (on behalf of PlanetIQ), and unmanned surface vehicles (on behalf of Saildrone); and Title III, all provisions relating to production weather, oceanic and atmospheric research, system acquisition, and research supercomputing (on behalf of Cray). H.R. 2968 /S. 2474, Department of Defense Appropriations Act, 2020, Title III, all provisions relating to Navy shipbuilding (on behalf of Austal USA), unmanned aerial vehicles (on behalf of General Atomics Aeronautical Systems Inc), high performance computing (on behalf of Cray and Hewlett-Packard Enterprise), edge computing (on behalf of Hewlett-Packard Enterprise), tactical radios (on behalf of Thales USA), and surveying equipment or systems (on behalf of Trimble); Title IV, all provisions relating to assured access to space (on behalf of Arianespace), ship development (on behalf of Austal USA), biomedical technology (on behalf of Battelle Memorial Institute), high performance computing (on behalf of Cray and Hewlett Packard Enterprise), edge computing (on behalf of Hewlett-Packard Enterprise), advanced power electronics (on behalf of Cree), tactical and intelligence data analysis (on behalf of Esri), unmanned aerial vehicles (on behalf of General Atomics Aeronautical Systems Inc), unexplained physiological episode research and human performance in extreme environments (on behalf of the Florida Institute for Human Machine Cognition), weather data (on behalf of PlanetiQ), aerospace sensors and technology transition (on behalf of Wright State Research Institute), major test and evaluation investment (on behalf of SRI International); and title VI, all provisions relating to blood products (on behalf of Cerus). H.R. 2960 /S. 2740 Energy and Water Development Act, 2020, Title III, all provisions relating to advanced scientific computing research and advanced simulation and computing (on behalf of Cray and Hewlett-Packard Enterprise), and advanced robotics (on behalf of Florida Institute for Human Machine Cognition). H.R. 3052/S. 2580, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2020, Title I, all provisions relating to U.S. Geological Surveys maps (on behalf of Esri) and U.S. Park Service procurement of surveying equipment or systems (on behalf of Trimble). H.R. 3931/S. 2582, Department of Homeland Security Appropriations Act, 2020, Title II, all provisions relating to enterprise information geospatial services (on behalf of ESRI). H.R. 2740/S. ____Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2020, Title II, all provisions relating to blood products (on behalf of Cerus). H.S. 3163 /S. 2520 Department of Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act, 2020, Title I, all provisions relating to use of geospatial technologies (on behalf of Esri) and funding for infrastructure (on behalf of Trimble).
Client expense: Not reported · Firm income: $10,000
2019 · third_quarter · Budget/Appropriations
H.R.2968 / S.2474, Department of Defense Appropriations Act, 2020, Titles III and IV, all provisions relating to High Performance Computing and Advanced Technology. H.R.2960 / S.2740, Energy and Water Development and Related Agencies Appropriations Act, 2020, Title III, all provisions relating to Advanced Simulation and Computing; Title III, all provisions relating to Advanced Scientific Computing Research. H.R.3055 / S.2584, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2020, Title III, all previsions relating to NOAA supercomputing.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · third_quarter · Budget/Appropriations
Issues related to FY 2020 Energy and Water Appropriations bills (H.R. 2470/S. 2740).
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Oceanic & Atmospheric Administration (NOAA), SENATE, U.S. Coast Guard (USCG), U.S. Fish & Wildlife Service (USFWS)
2019 · third_quarter · Budget/Appropriations
H.R.2960/S.2740, Energy and Water Development and Related Agencies Appropriations Act, FY2020, Channel deepening issues Monitor Infrastructure Plan, Channel deepening issues
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE